Skip to main content
Home
  • HOME
  • INFORMATION
    • Background
    • Patient Information and FAQ's
    • Meet the Team
    • Data Protection
  • PASHION SITES
  • CONTACT US
User account menu
  • Log in

Welcome to the PASHiOn Trial

  • PASHiOn
    PASHiOn
    Welcome to the PASHiOn Trial

Why the PASHiOn Trial?

Knee osteoarthritis (OA) is common, painful, progressive and disabling, and has significant personal and societal burden, particularly in an ageing population. Whilst knee replacement is successful for very late stage disease, it is inappropriate for earlier stages leaving few effective treatments available for patients in the “treatment gap” between symptom free and late-stage arthritis. High Tibial Osteotomy (HTO) is a proven surgical treatment providing good long-term outcome, reducing pain and improving function. It is suitable for early to mid-stage knee arthritis and has enormous potential to fill the “treatment gap” for many knee arthritis sufferers.

HTO provides an effective for these patients by correcting the alignment of the knee joint loading and therefore modifying the disease progression. A new method (ToKa) has been devised involving personalisation and digital planning. This method uses a custom personalised surgical guide and plate which potentially overcome existing technical limitations.

The aim of the PASHiOn Trial is to assess whether, in patients with early to mid-stage osteoarthritis of the knee, a personalised digitally planned HTO with custom 3D printed patient specific surgical guides and plate produce a more accurate correction and results in better outcomes compared to standard HTO performed with a “one-size fits all” plate.

QUICK INFORMATION

What is PASHiOn?

PASHiOn is a two group blinded randomised trial. Patients will be allocated to ToKa or standard HTO. Patients and assessors will be blinded to the treatment allocation.

Measurements pre-operation and at 6 months will include assessments of surgical accuracy using X-rays, dynamic assessment, length of operation, self-reported outcome and health resource use. 

Quick Links

Patient Information and FAQ's

Data Protection

LATEST NEWS

 

Tweets by PashionStudy

 

PASHiOn SUPPORTERS

SPONSOR

The University of Bath

Funder

Versus Arthritis

Trial Management

The Surgical Intervention Trials Unit (SITU), which is part of the UKCRN reistered Oxford Clinical Trials Research Unit (OCTRU) at The University of Oxford.

Recruitment Progress:

93
56

Date of latest recruit:

11 December, 2023

Site of latest recruit:

PASHiOn - Royal Orthopaedic Hospital NHS Foundation Trust
  • University of BATH
  • Versus Arthritis
  • NDORMS logo
  • SITU logo
  • OCTRU logo
Trial Information

Sponsor: University of Bath

Funder: Versus Arthritis

IRAS ID: 280261

Newsletters

Coming soon...

 

Email

pashion@ndorms.ox.ac.uk

Postal Address

The PASHiOn Study Team

Surgical Intervention Trials Unit